Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Significant Growth in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 457,500 shares, an increase of 90.3% from the December 31st total of 240,400 shares. Approximately 3.2% of the shares of the company are sold short. Based on an average daily trading volume, of 3,640,000 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new stake in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned approximately 1.17% of Virpax Pharmaceuticals as of its most recent filing with the SEC. Institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Price Performance

NASDAQ:VRPX traded up $0.01 during midday trading on Wednesday, hitting $0.30. 110,516 shares of the stock were exchanged, compared to its average volume of 437,565. The business has a 50-day moving average price of $0.38 and a two-hundred day moving average price of $0.68. Virpax Pharmaceuticals has a one year low of $0.23 and a one year high of $5.48.

Wall Street Analyst Weigh In

Separately, Maxim Group restated a “hold” rating on shares of Virpax Pharmaceuticals in a report on Wednesday, October 9th.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.